liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
Region Östergötland, Centrum för kirurgi, ortopedi och cancervård, Hematologiska kliniken US.
Kristianstad Central Hospital, Sweden.
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, ISSN 0145-2126, E-ISSN 1873-5835, Vol. 39, nr 1, s. 33-37Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximabin chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for rituximab-containing therapy were eligible. Ninety-six patients from 19 centers were enrolled. The most common regimen was rituximab, fludarabine and cyclophosphamide. Fifty-six patients experienced ADR during rituximab infusion. Reactions greater than= grade 3 occurred in five patients and no cases of tumor lysis syndrome were recorded. Despite a high number of circulating tumor cells few severe ADR were noted. Thus, rituximab containing regimens can be considered safe for CLL patients in general practice.

Ort, förlag, år, upplaga, sidor
Elsevier , 2015. Vol. 39, nr 1, s. 33-37
Nyckelord [en]
Adverse reaction; Chronic lymphocytic leukemia; Rituximab; Therapy
Nationell ämneskategori
Hematologi
Identifikatorer
URN: urn:nbn:se:liu:diva-114250DOI: 10.1016/j.leukres.2014.09.019ISI: 000346858200005PubMedID: 25499233OAI: oai:DiVA.org:liu-114250DiVA, id: diva2:788637
Anmärkning

Funding Agencies|Roche Sweden AB [ML22754]

Tillgänglig från: 2015-02-16 Skapad: 2015-02-16 Senast uppdaterad: 2017-12-04

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed
Av organisationen
Hematologiska kliniken US
I samma tidskrift
Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis
Hematologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 87 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf